SALV.L Share News (SALV)

SalvaRx Shares To Be Cancelled On London Stock Exchange

SalvaRx Shares To Be Cancelled On London Stock Exchange

SalvaRx Will Not Close Reverse Takeover Before AIM Cancellation Date

SalvaRx Will Not Close Reverse Takeover Before AIM Cancellation Date

SalvaRx Turns To Interim Profit, Evaluating Takeover Opportunities

SalvaRx Turns To Interim Profit, Evaluating Takeover Opportunities

SalvaRx Sees Shares Suspended Following Failure To Complete Deal

(Alliance News) - Shares in cash shell SalvaRx Group PLC were suspended on Tuesday as it has failed to meet AIM rules regarding a takeover.SalvaRx had until Tuesday to make an acquisition a

SalvaRX Loss Widens, Mulling Options Ahead Of Cash Shell AIM Deadline

(Alliance News) - SalvaRX Group PLC said on Friday its annual loss widened following the disposal of its SalvaRx Ltd stake, with the cash shell continuing to evaluate its options.The a loss

Pires Investments Net Asset Value Rises 27% On Good Investments

LONDON (Alliance News) - Pires Investments PLC on Friday reported a 27% rise in the value of its unaudited net assets driven by a good performance of two of its major investments.As at the

SalvaRx Group Interim Loss Widens On Exceptional Charge

LONDON (Alliance News) - SalvaRx Group PLC on Thursday reported a widened interim loss on an impairment charge.In the six months ended June, the drug development company focused on for its

SalvaRx Awaits Review Of Portage Biotech Circular

LONDON (Alliance News) - SalvaRx Group PLC said Tuesday that a shareholder circular from Portage Biotech Inc has been submitted to the Canadian Securities Exchange for review.Earlier this a

SalvaRx offloads immuno-oncology assets to Portage Biotech

(Sharecast News) - AIM-listed biotechnology company SalvaRx has entered into a conditional sale agreement that would see the Cambridgeshire-based firm offload its immuno-oncology assets to Portage Biotech.

SalvaRx Group Shares Jump 76% As It Sells Interest In Subsidiary (ALLISS)

LONDON (Alliance News) - Shares in SalvaRx Group PLC soared on Tuesday after the company said it entered into a sale agreement for the disposal of its 94.2% stake in SalvaRx Ltd to Portage Biotech

SalvaRx's iOx Therapeutics Reports Delay In IMM60 Manufacturing

LONDON (Alliance News) - SalvaRx Group PLC said on Monday its subsidiary iOx Therapeutics Ltd has seen a significant delay in manufacturing its lead drug candidate IMM60.The cancer biotech

SalvaRx Reports Positive Progress From Investee Companies

LONDON (Alliance News) - Biotechnology firm SalvaRx Group PLC said Thursday it is making progress across all aspects of its business as it looks to gather safety and efficacy

SalvaRx Expects To Start Clinical Trial This Year, Posts Annual Loss

SalvaRx takes chunk of Intensity Therapeutics

(ShareCast News) - Cancer-focused biotechnology firm SalvaRx expanded its investment portfolio on Friday, taking a chunk of US-based Intensity Therapeutics - an outfit pioneering a new approach to treating solid tumours. The AIM-traded company confirmed it invested $2m in cash for a 9.2% interest in

SalvaRx Invests In Intensity Therapeutics, Issues Notes To Directors (ALLISS)